PACIRA BIOSCIENCES, INC. (PCRX)

Import this data to Google Sheets with:

=jivedata("PCRX","financials")

Full statements spill as a table. For one cell: =jivedata("PCRX","Revenue") or =jivedata("PCRX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

PACIRA BIOSCIENCES, INC.

PCRX • CIK 0001396814

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$87,675	$-73,371	$19,191	$19,871
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$61,701	$-63,106	$16,874	$17,648
Income Tax Expense (Benefit)	$19,746	$36,454	$9,840	$3,010
Net Income (Loss) Attributable to Parent	$41,955	$-99,560	$7,034	$14,638
Revenue from Contract with Customer, Excluding Assessed Tax	$674,978	—	$726,411	$746,164
Cost of Revenue	$184,669	$170,428	$149,749	$155,154
Research and Development Expense	$76,257	$81,577	$117,312	$121,734
Selling, General and Administrative Expense	$269,441	$294,099	$368,759	$379,158
Amortization of Intangible Assets	$57,288	$57,288	$57,288	$57,288
Goodwill, Impairment Loss	—	$163,243	$0	$0
Costs and Expenses	$587,303	—	$707,220	$726,293
Investment Income, Interest	$11,444	$19,689	$22,732	$14,703
InterestExpenseNonoperating	—	$16,569	$17,446	$15,492
Gain (Loss) on Extinguishment of Debt	$-16,926	$7,518	$-983	$-983
Other Nonoperating Income (Expense)	$-186	$-373	$-6,620	$-451
Nonoperating Income (Expense)	$-25,974	—	$-2,317	$-2,223
Weighted Average Number of Shares Outstanding, Basic	46,222,000	46,245,000	44,566,000	38,660,000
Weighted Average Number of Shares Outstanding, Diluted	51,979,000	46,245,000	45,042,000	39,780,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$153,298	$276,774	$158,545	$205,875
Short-term Investments	$125,283	$207,841	$79,879	$45,156
Property, Plant and Equipment, Net	$173,927	$167,169	$140,690	$130,277
Accounts Receivable, after Allowance for Credit Loss, Current	$105,556	$113,304	$124,069	$132,420
Operating Lease, Right-of-Use Asset	$61,020	$49,222	$41,777	$44,920
Inventory, Net	$104,353	$125,282	$152,863	$134,575
Goodwill	$163,243	$0	$20,214	$19,642
Prepaid Expense and Other Assets, Current	$21,504	$21,929	$32,618	$29,852
Intangible Assets, Net (Excluding Goodwill)	$483,258	$425,970	$368,100	$285,484
Assets, Current	$509,994	$745,130	$547,974	$615,215
Deferred Income Tax Assets, Net	$144,485	$130,376	$123,854	$124,598
Assets	$1,574,386	$1,553,516	$1,264,917	$1,243,978
Long-term Debt, Excluding Current Maturities	—	—	$372,189	$363,124
Operating Lease, Liability, Noncurrent	$54,806	$44,645	$36,176	$38,695
Deferred Income Tax Liabilities, Net	—	—	$4,213	$4,070
Other Liabilities, Noncurrent	$13,573	$16,817	$20,572	$26,650
Liabilities	$704,256	$775,168	$571,806	$572,002
Accounts Payable, Current	$15,698	$19,133	$15,150	$17,509
Accrued Liabilities, Current	$64,243	$80,124	$95,601	$93,499
Operating Lease, Liability, Current	$8,801	$8,887	$9,839	$10,298
Long-term Debt, Current Maturities	—	—	$0	$0
Liabilities, Current	$97,383	$309,920	$120,590	$122,011
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$46	$47	$48	$49
Treasury Stock, Common, Value	—	$25,121	$176,565	$227,013
Additional Paid in Capital	$976,633	$1,009,435	$1,064,623	$1,087,452
Retained Earnings (Accumulated Deficit)	$-106,796	$-206,356	$-199,322	$-191,753
Accumulated Other Comprehensive Income (Loss), Net of Tax	$247	$343	$4,327	$3,241
Stockholders' Equity Attributable to Parent	$870,130	$778,348	$693,111	$671,976
Preferred Stock, Shares Authorized	5,000,000	5,000,000	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000	250,000,000	250,000,000
Common Stock, Shares, Issued	46,481,174	47,077,844	47,890,777	48,840,889
Common Stock, Shares, Outstanding	46,481,174	46,240,604	41,116,739	39,822,298
Treasury Stock, Common, Shares	—	837,240	6,774,038	9,018,591

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	—	—	$-77	$-243
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$49,159	$123,476	$-118,229	$-94,609
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$153,298	$276,774	$158,545	$19,241
Net Income (Loss) Attributable to Parent	$41,955	$-99,560	$7,034	$14,638
Net Cash Provided by (Used in) Operating Activities	$154,649	$189,389	$151,994	$187,663
Payments to Acquire Businesses, Net of Cash Acquired	$0	—	$16,702	$335
Payments to Acquire Property, Plant, and Equipment	$15,161	$10,636	$15,333	$8,148
Payments to Acquire Short-term Investments	$137,608	$252,212	$141,041	$70,261
Proceeds from Sale of Short-term Investments	$237,068	$179,572	$273,807	$172,891
Payments to Acquire Long-term Investments	$6,758	$0	$1,250	$0
Net Cash Provided by (Used in) Investing Activities	$77,541	$-83,276	$99,481	$94,147
Proceeds from Stock Options Exercised	$1,939	$0	$502	$961
Payment, Tax Withholding, Share-based Payment Arrangement	$106	$491	$5,617	$7,999
Payments for Repurchase of Common Stock	—	$25,000	$148,328	$148,334
Proceeds from Lines of Credit	—	—	$101,000	$101,000
Proceeds from Convertible Debt	—	$287,500	$0	$0
Proceeds from Issuance of Secured Debt	—	—	$0	$0
Repayments of Lines of Credit	—	—	$10,000	$20,000
Payments for Derivative Instrument, Financing Activities	—	$26,709	$0	$0
Payment for Debt Extinguishment or Debt Prepayment Cost	$5,750	$0	$0	$0
Payment of Financing and Stock Issuance Costs	$1,163	$9,350	$2,186	$2,186
Net Cash Provided by (Used in) Financing Activities	$-183,031	$17,363	$-369,627	$-376,176
Interest Paid, Excluding Capitalized Interest, Operating Activities	$27,635	$15,418	$15,235	$13,719
Capital Expenditures Incurred but Not yet Paid	$1,982	$5,565	$1,468	$1,543
ShareRepurchaseProgramExciseTaxPayable	—	$121	$1,324	$1,727
Goodwill, Impairment Loss	—	$163,243	$0	$0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$0	$0	$25,866	$25,866
Equity Method Investment, Other than Temporary Impairment	$0	$0	$11,000	$0
Gain (Loss) on Termination of Lease	—	$-2,165	$0	$0
Deferred Income Taxes and Tax Credits	—	—	$6,477	$9,972
Depreciation, Depletion and Amortization	$75,574	$78,785	$91,023	$85,159
Amortization of Debt Issuance Costs and Discounts	—	—	$2,997	$2,412
Gain (Loss) on Extinguishment of Debt	$-16,926	$7,518	$-983	$-983
Share-based Payment Arrangement, Noncash Expense	$47,895	$51,171	$57,502	$55,974
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$-3,424	$-4,457	$-2,175	$243
Accretion (Amortization) of Discounts and Premiums, Investments	—	—	$4,927	$2,410
Provision for Other Losses	$2,137	$236	$-5,520	$367
Increase (Decrease) in Accounts Receivable	$7,159	$7,748	$10,742	$21,770
Increase (Decrease) in Inventories	$8,290	$20,929	$27,567	$-3,755
Increase (Decrease) in Prepaid Expense and Other Assets	$9,639	$7,360	$1,212	$-17,801
Increase (Decrease) in Accounts Payable	$916	$3,084	$-5,598	$-12,694
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	—	—	$6,853	$6,853

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("PCRX","financials")

Full statements spill as a table. For one cell: =jivedata("PCRX","Revenue") or =jivedata("PCRX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.